OBJECTIVE: We sought to determine if an association exists between the use of histamine-2 receptor (H2) blockers and the incidence of necrotizing enterocolitis (NEC) in infants of 401 to 1500 g in birth weight. STUDY DESIGN: Data from the National Institute of Child Health and Human Development Neonatal Research Network very low birth weight (401-1500 g) registry from September 1998 to December 2001 were analyzed. The relation between the diagnosis of NEC (Bell stage II or greater) and antecedent H2-blocker treatment was determined by using case-control methodology. Conditional logistic regression was implemented, controlling for gender, site of birth (outborn versus inborn), Apgar score of < 7 at 5 minutes, and postnatal steroids. RESULTS: Of 11072 infants who survived for at least 12 hours, 787 (7.1%) developed NEC (11.5% of infants 401-750 g, 9.1% of infants 751-1000 g, 6.0% of infants 1001-1250 g, and 3.9% of infants 1251-1500 g). Antecedent H2-blocker use was associated with an increased incidence of NEC (P < .0001). CONCLUSIONS: H2-blocker therapy was associated with higher rates of NEC, which is in agreement with a previous randomized trial of acidification of infant feeds that resulted in a decreased incidence of NEC. In combination, these data support the hypothesis that gastric pH level may be a factor in the pathogenesis of NEC.
OBJECTIVE: We sought to determine if an association exists between the use of histamine-2 receptor (H2) blockers and the incidence of necrotizing enterocolitis (NEC) in infants of 401 to 1500 g in birth weight. STUDY DESIGN: Data from the National Institute of Child Health and Human Development Neonatal Research Network very low birth weight (401-1500 g) registry from September 1998 to December 2001 were analyzed. The relation between the diagnosis of NEC (Bell stage II or greater) and antecedent H2-blocker treatment was determined by using case-control methodology. Conditional logistic regression was implemented, controlling for gender, site of birth (outborn versus inborn), Apgar score of < 7 at 5 minutes, and postnatal steroids. RESULTS: Of 11072 infants who survived for at least 12 hours, 787 (7.1%) developed NEC (11.5% of infants 401-750 g, 9.1% of infants 751-1000 g, 6.0% of infants 1001-1250 g, and 3.9% of infants 1251-1500 g). Antecedent H2-blocker use was associated with an increased incidence of NEC (P < .0001). CONCLUSIONS: H2-blocker therapy was associated with higher rates of NEC, which is in agreement with a previous randomized trial of acidification of infant feeds that resulted in a decreased incidence of NEC. In combination, these data support the hypothesis that gastric pH level may be a factor in the pathogenesis of NEC.
Authors: Bahubali Gane; B Vishnu Bhat; B Adhisivam; Rojo Joy; P Prasadkumar; P Femitha; B Shruti Journal: Indian J Pediatr Date: 2014-01-04 Impact factor: 1.967
Authors: Steven W Graves; Michael S Esplin; Paula McGee; Dwight J Rouse; Kenneth J Leveno; Brian M Mercer; Jay D Iams; Ronald J Wapner; Yoram Sorokin; John M Thorp; Susan M Ramin; Fergal D Malone; Mary J O'Sullivan; Alan M Peaceman; Gary D V Hankins; Donald J Dudley; Steven N Caritis Journal: Am J Obstet Gynecol Date: 2013-11-08 Impact factor: 8.661
Authors: Sudarshan R Jadcherla; Jonathan L Slaughter; Michael R Stenger; Mark Klebanoff; Kelly Kelleher; William Gardner Journal: Hosp Pediatr Date: 2013-10
Authors: Miguel Sáenz de Pipaón Marcos; Juan Rodríguez Delgado; Miriam Martínez Biarge; Jesús Pérez Rodríguez; Grevelyn Sosa Rotundo; Juan A Tovar Larrucea; José Quero Jiménez Journal: Pediatr Surg Int Date: 2008-05-06 Impact factor: 1.827